Ann: Investor Presentation, page-103

and @edgck, If I can male a suggestion, review all of VRS37 posts carefully. This person is an ill informed person who just posts stuff with no clinical correlation

1) Rituximab as a drug has been used in most of these rare conditions when standard lines of treatment have failed or show no improvement. If you do a quick search on pubmed for rituximab in FSGS you will see that there are calls for a randomised controlled study (of which none have been done yet that I am aware of, happy to be corrected). So as such, clinicians are using it in cases to either buy time prior to a transplant or using it in post transplant patients.

2) From the above statement, what DXB are trying to achieve is a first of its kind in the treatment for FSGS. Once this commercialises, it would have been a drug that has been studied in all phase trials and shown to have a beneficial effect, unlike rituximab which has no randomised trials.

if rituximab is a cheaper option, its only observational. There would have to be a proper study done to compare the DXB with Rituximab to show that efficacy is same/better/worse from a price perspective.

So from the box that VRS37 put up, it is only a matter of time before that flowchart is revised once Dimerix hits the market.

DYOR